A New IV Infusion Option for Alzheimer's
TB006 EXPANDED ACCESS | WESTLAKE VILLAGE – GREATER LOS ANGELES
TB006 is an investigational monoclonal antibody developed by TrueBinding, Inc. For eligible patients with Alzheimer’s disease and related dementias, it is available through an FDA-authorized Expanded Access Program.
BrainThrive provides neurologist-led evaluation, enrollment, infusion, and follow-up through our Alzheimer’s Infusion Center in Westlake Village, serving families across Greater Los Angeles and Southern California.
TB006 is investigational. Its safety and effectiveness have not been established by adequate and well-controlled clinical trials.
Get a Call from Us!
Why BrainThrive Chose TB006
TB006 is currently the only Alzheimer’s infusion BrainThrive has chosen to offer.
That decision reflects its distinct biological target – Galectin-3 – and the preliminary human clinical and safety data reported by TrueBinding.
Our approach is selective. Each patient is reviewed individually to determine whether the clinical picture and Expanded Access requirements support moving forward.
A Different Target: Galectin-3
Alzheimer’s disease is complex and does not arise from a single pathway. Galectin-3 is a protein involved in inflammatory signaling and protein interactions that researchers are studying across neurodegenerative disease.
One way to understand Galectin-3 is as a kind of biological “glue.” It can bind with other molecules and participate in inflammatory and aggregation-related processes. TB006 is designed to bind Galectin-3 and block
its activity.
TB006
Galectin -3
Blocks Its Activity
Whether this mechanism translates into meaningful clinical benefit is still being studied.
What the Early Clinical Data Show
TB006 has completed a randomized, placebo-controlled Phase 1b/2a proof-of-concept study in Alzheimer’s
disease (NCT05074498).
CDR-SB – cognition + function
At Day 104, TrueBinding reported a 0.44-point treatment difference favoring TB006 over placebo on CDR-SB (p=0.08). This was a favorable trend, but it did not meet conventional statistical significance.
MMSE – cognitive performance
At Day 36, TrueBinding reported a 1.02-point improvement favoring TB006 over placebo on MMSE (p=0.02), a secondary endpoint.
These are preliminary, sponsor-reported findings from an early-stage proof-of-concept study. They do not establish that TB006 is effective and cannot predict how an individual patient will respond.
Safety Experience
TrueBinding reported that TB006 was generally well tolerated during the Phase 1b/2a observation period. Infusion reactions were the most common adverse event. The sponsor reported no treatment-related serious adverse events and no safety signals in clinical laboratory evaluations, imaging, or ECGs.
TB006 remains investigational. Unexpected adverse events or toxicities may occur, and ongoing safety monitoring is required.
Why TB006 Is Available Through Expanded Access
Expanded Access – sometimes called compassionate use – is an FDA pathway that can allow patients with serious or life-threatening conditions to receive an investigational treatment outside a clinical trial when specific criteria are met.
For TB006, those requirements include considerations such as whether a comparable or satisfactory alternative is available, whether participation in an appropriate clinical trial is possible, and whether the potential benefit justifies the potential risks.
FDA authorization of Expanded Access is not FDA approval of TB006. TB006 remains investigational.
Could TB006 Be an Option?
BrainThrive guides families through the eligibility and Expanded Access process. A formal review may include:
- The dementia diagnosis and current cognitive status
- Prior dementia treatments and the response to them
- Current medications and overall medical stability
- Recent laboratory testing, cardiac evaluation, and brain imaging
- Whether an appropriate clinical trial is available
- A required LGALS3 genetic screen using a cheek swab
Final eligibility depends on the current program criteria, medical review, and required enrollment process.
From First Call to Infusion
1. Eligibility Call
Call BrainThrive or request a callback. We can answer initial questions, explain the Expanded Access pathway and private-pay nature of treatment, and determine whether a formal neurologist review appears reasonable.
2. Neurologist Review
Our clinical team reviews the diagnosis, treatment history, medical records, current health status, and existing testing relevant to eligibility.
3. Screening and Enrollment
If further evaluation is appropriate, BrainThrive coordinates the required screening, consent, records, and Expanded Access enrollment process.
4. Infusion and Follow-Up
If approved, TB006 is administered by IV under neurologist-led medical supervision. The current protocol generally calls for treatment about every 28 days, and the infusion itself is generally about one hour. Ongoing monitoring and caregiver communication continue throughout care.
Costs and what is included are reviewed directly with families before treatment decisions are made.
Neurologist-Led From Evaluation Through Infusion
TB006 at BrainThrive is provided within a neurology practice, not as a stand-alone infusion service.
Yul Rapoport, DO
BOARD-CERTIFIED NEUROLOGIST | PRINCIPAL INVESTIGATOR
Dr. Rapoport personally oversees each patient’s TB006 care and is physically present for every infusion. He brings extensive experience evaluating and treating people with Alzheimer’s disease and related dementias.
One Clinical Team
The same BrainThrive team reviews records, guides the Expanded Access process, coordinates treatment, and follows the patient through ongoing care.
Caregiver Communication
Families and caregivers are included in planning and follow-up because dementia care depends on clear communication with the people who know the patient best.
A Private Lakeside Treatment Setting
BrainThrive’s Westlake Village center offers a private lakeside environment designed for comfort, privacy, and careful medical monitoring.
Serving Greater Los Angeles and Southern California
BrainThrive’s Alzheimer’s Infusion Center is located in Westlake Village and welcomes inquiries from families throughout Greater Los Angeles, Ventura County, and Southern California.
Initial conversations and high-level record review can begin remotely, allowing families to determine whether a formal evaluation appears reasonable before traveling.
For physicians, care managers, and senior-living professionals: BrainThrive welcomes professional referrals and can discuss coordinated evaluation, caregiver communication, and appropriately structured treatment arrangements.
For select patients, BrainThrive can also evaluate whether treatment may be arranged in a home or senior-living community when clinically appropriate.
Frequently Asked Questions
Is TB006 FDA-approved?
No. TB006 is investigational and is available to eligible patients through an FDA-authorized Expanded Access Program. It is not FDA approved as a commercial Alzheimer’s treatment.
Is Expanded Access a clinical trial?
No. Expanded Access is a regulatory pathway that can provide eligible patients access to an investigational treatment outside a clinical trial when specific requirements are met.
Does everyone qualify?
No. Eligibility depends on medical and program criteria and requires review.
How often is TB006 given?
The current protocol generally calls for IV treatment approximately every 28 days, with allowable scheduling flexibility.
Is TB006 covered by insurance?
TB006 Expanded Access is a private-pay pathway. Costs and what is included are reviewed directly with families before treatment decisions are made.
Can the process begin before we travel to BrainThrive?
Yes. An initial conversation and high-level review can begin remotely to determine whether moving to a formal evaluation appears reasonable.
Can BrainThrive predict whether TB006 will help?
No. TB006 remains investigational, and individual benefit cannot be predicted or guaranteed.
Can treatment ever be provided outside BrainThrive?
For select patients and settings, BrainThrive can evaluate whether an appropriately structured home or senior-living treatment arrangement is possible.
Find Out Whether TB006 May Be an Option
If you are considering TB006 for yourself or someone you care about, speak with the BrainThrive team. We can explain the Expanded Access pathway and help determine whether a formal neurologist review may be appropriate.
You do not have to make a treatment decision to begin the conversation.
Learn More From Primary Sources
TrueBinding Expanded Access: truebinding.com/expanded-access
Phase 1b/2a clinical trial: ClinicalTrials.gov NCT05074498
Expanded Access Program: ClinicalTrials.gov NCT05959239
Phase 1b/2a sponsor-reported results: TrueBinding press release, November 18, 2022
TB006 is an investigational monoclonal antibody developed by TrueBinding, Inc. Its safety and effectiveness have not been established by adequate and well-controlled clinical trials. Access is limited to eligible patients through the applicable Expanded Access process. Individual results cannot be predicted or guaranteed.
Clinical trial: NCT05074498 | Expanded Access: NCT05959239
818.877.7000
info@brainthrive.com
32123 Lindero Canyon Rd., Suite 210
Westlake Village, CA 91361